Financial reports
10-Q
2024 Q1
Quarterly report
15 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
10-K
2023 FY
Annual report
16 Apr 24
NT 10-K
Notice of late annual filing
28 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
13 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
Current reports
8-K
VBI Vaccines Provides an Update on its Restructuring Proceedings
2 Aug 24
8-K
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
30 Jul 24
8-K
VBI Vaccines Announces Results of Annual General Meeting
25 Jun 24
8-K
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
29 May 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 May 24
8-K
VBI Vaccines Reports First Quarter 2024 Financial Results
15 May 24
8-K
Other Events
1 May 24
8-K
VBI Vaccines Reports Full Year 2023 Financial Results
16 Apr 24
8-K
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11 Apr 24
8-K
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
3 Apr 24
Registration and prospectus
25-NSE
Exchange delisting
6 Sep 24
424B5
Prospectus supplement for primary offering
15 May 24
424B5
Prospectus supplement for primary offering
11 Apr 24
424B5
Prospectus supplement for primary offering
7 Jul 23
424B5
Prospectus supplement for primary offering
7 Jul 23
424B5
Prospectus supplement for primary offering
5 Jul 23
D
$0 in equity / options / securities to be acquired, 1 investor
28 Sep 22
S-8
Registration of securities for employees
26 Aug 22
S-3
Shelf registration
26 Aug 22
424B5
Prospectus supplement for primary offering
3 Sep 21
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
DEFA14A
Additional proxy soliciting materials
2 May 23
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
PRE 14A
Preliminary proxy
18 Apr 22
DEF 14A
Definitive proxy
26 Apr 21
DEFA14A
Additional proxy soliciting materials
26 Apr 21
Other
EFFECT
Notice of effectiveness
7 Sep 22
CORRESP
Correspondence with SEC
2 Sep 22
UPLOAD
Letter from SEC
2 Sep 22
CT ORDER
Confidential treatment order
11 Mar 19
EFFECT
Notice of effectiveness
30 Jul 18
CORRESP
Correspondence with SEC
26 Jul 18
UPLOAD
Letter from SEC
26 Jul 18
EFFECT
Notice of effectiveness
8 Jun 17
CORRESP
Correspondence with SEC
6 Jun 17
CORRESP
Correspondence with SEC
5 Jun 17
Ownership
SC 13D/A
PERCEPTIVE ADVISORS LLC
17 Apr 24
SC 13D/A
PERCEPTIVE ADVISORS LLC
20 Nov 23
4
Michel DeWilde
31 Jul 23
4
Damian Braga
31 Jul 23
4
Jeff Baxter
28 Jul 23
4
Joanne Cordeiro
28 Jul 23
4
Nell Beattie
28 Jul 23
4
VAUGHN B HIMES
28 Jul 23
4
Avi Mazaltov
28 Jul 23
4
Francisco Diaz-Mitoma
28 Jul 23